Title:
APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA
Document Type and Number:
WIPO Patent Application WO/2019/140937
Kind Code:
A1
Abstract:
An application of anlotinib and a pharmaceutically acceptable salt thereof in the preparation of a drug which inhibits or treats osteosarcoma.
Inventors:
HUA YINGQI (CN)
WANG GANGYANG (CN)
CAI ZHENGDONG (CN)
WANG ZHUOYING (CN)
ZHANG TAO (CN)
WANG HONGSHENG (CN)
SUN MENGXIONG (CN)
WANG GANGYANG (CN)
CAI ZHENGDONG (CN)
WANG ZHUOYING (CN)
ZHANG TAO (CN)
WANG HONGSHENG (CN)
SUN MENGXIONG (CN)
Application Number:
PCT/CN2018/106625
Publication Date:
July 25, 2019
Filing Date:
September 20, 2018
Export Citation:
Assignee:
SHANGHAI GENERAL HOSPITAL (CN)
International Classes:
A61K31/4709; A61P35/00
Foreign References:
CN107970241A | 2018-05-01 | |||
CN101809012A | 2010-08-18 |
Other References:
GAO, TIAN ET AL.: "Advances in Molecular Targeted Therapy for Soft Tissue Sarcomas", CHINESE JOURNAL OF CLINICAL ONCOLOGY, vol. 44, no. 1, 31 January 2017 (2017-01-31), pages 9
LI, XIAOQIN ET AL.: "Expression of C-kit Receptor and Platelet-Derived Growth Factor Receptor-a in Osteosarcoma and their Significance", CHINESE JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol. 29, no. 8, 31 August 2013 (2013-08-31), pages 870
LI, XIAOQIN ET AL.: "Expression of C-kit Receptor and Platelet-Derived Growth Factor Receptor-a in Osteosarcoma and their Significance", CHINESE JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol. 29, no. 8, 31 August 2013 (2013-08-31), pages 870
Attorney, Agent or Firm:
SHANGHAI ZHUOYANG INTELLECTUAL PROPERTY AGENT FIRM (CN)
Download PDF: